Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

NT-proBNP as a useful tool in diagnosing incomplete Kawasaki disease

불완전 가와사끼병에서 NT-proBNP의 진단적 역할

  • Lee, Dong-Won (Department of Pediatrics, Kyungpook National University School of Medicine) ;
  • Kim, Yeo-Hyang (Departments of Pediatrics, Keimyung University School of Medicine) ;
  • Hyun, Myung-Chul (Department of Pediatrics, Kyungpook National University School of Medicine) ;
  • Kwon, Tae-Chan (Departments of Pediatrics, Keimyung University School of Medicine) ;
  • Lee, Sang-Bum (Department of Pediatrics, Kyungpook National University School of Medicine)
  • 이동원 (경북대학교 의학전문대학 소아과학교실) ;
  • 김여향 (계명대학교 의과대학 소아과학교실) ;
  • 현명철 (경북대학교 의학전문대학 소아과학교실) ;
  • 권태찬 (계명대학교 의과대학 소아과학교실) ;
  • 이상범 (경북대학교 의학전문대학 소아과학교실)
  • Received : 2010.01.25
  • Accepted : 2010.03.02
  • Published : 2010.04.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : To determine the efficacy of the N-terminal fragment of B-type natriuretic peptide (NT-proBNP) as a useful diagnostic method in children with incomplete Kawasaki disease (KD). Methods : Ninety-six patients who were diagnosed as having KD between January 2008 and June 2009 were enrolled in the study. American Heart Association recommendations for diagnosis were used, and patients were divided into the complete KD and incomplete KD groups. Blood tests including NT-proBNP were performed on admission day. Nineteen patients who had other febrile diseases other than KD were enrolled as control. Results : Thirty-three patients (34%) had incomplete KD. Change in the lips and oral cavity and conjunctivitis were the most common clinical features, but their frequency was lower than complete KD (76% vs 98%, 76% vs 90%). Patients with incomplete KD exhibited significantly higher NT-proBNP level than that of control ($1,407.7{\pm}1633.5pg/mL$ vs $126.2{\pm}135.5pg/mL$, $P$<0.001). An NT-proBNP cutoff value of 158 pg/mL provided a sensitivity of 81% and a specificity of 74% for diagnosis of incomplete KD. Conclusion : NT-proBNP assay can be clinically useful for the diagnosis of incomplete KD, if the patient has persistent fever, change in the lips and oral cavity, and conjunctivitis, and if the patient with those symptoms is suspected to have incomplete KD.

목 적: 지속적인 발열과 3개 이하의 가와사끼병 진단 기준을 만족하는 환자군에서 불완전 가와사끼병을 감별하는데 있어 NT-proBNP가 가지는 진단적 의미를 살펴보고자 하였다. 방 법: 2008년 1월부터 2009년 6월까지 가와사끼병으로 진단 및 치료 받은 환자 96명을 대상으로 하였다. 진단은 입원 당일 열을 포함한 가와사끼병의 고전적인 진단 기준에 따랐고, 진단 기준의 만족 정도에 따라서 완전 가와사끼병 환자군과 불완전 가와사끼병 환자군으로 구분하였으며, NT-proBNP를 포함한 혈액검사를 시행하였다. 지속되는 열과 함께 3개 미만의 진단 기준을 만족하였지만 임상 경과와 여러 검사들을 통해 환자 19명을 대조군으로 하여 분석하였다. 결 과: 96명의 가와사끼병 환자 중 고전적인 진단 기준을 3가지 이하로 만족한 불완전 가와사끼병 환자는 33명으로 전체 가와사끼병 환자의 34% 였다. 임상 양상으로 구강 점막의 변화와 안검 충혈이 가장 많았는데 완전 가와사끼병에 비해 발생 빈도는 적었다(76% vs 98%, 76% vs 90%). 불완전 가와사끼병 환자의 NT-proBNP는 대조군에 비해 유의하게 높았으며($1407.7{\pm}1633.5pg/mL$ vs $126.2{\pm}135.5pg/mL$, $P$<0.001), cutoff value를 158 pg/mL으로 하였을 때 민감도 81%, 특이도 74% 로 C 반응성 단백 ${\geq}3mg/dL$의 민감도 74%, 특이도 68% 보다 높았지만, 적혈구 침강 속도 ${\geq}40mm/hr$의 민감도 70%, 특이도 84%로 특이도에서 적혈구 침강 속도보다 낮았다. 결 론: 지속되는 열, 안검 충혈, 구강 점막의 변화가 있어 불완전 가와사끼병으로 의심해야 하는 환자에서 NT-proBNP 검사를 시행하고 진단에 이용하는 것이 가와사끼병의 빠른 진단과 치료에 도움이 될 것이다.

Keywords

References

  1. Fukushige J, Takahashi N, Ueda Y, Ueda K. Incidence and clinical features of incomplete Kawasaki disease. Acta Paediatr 1994;83:1057-60. https://doi.org/10.1111/j.1651-2227.1994.tb12985.x
  2. Joffe A, Kabani A, Jadavji T. Atypical and complicated Kawasaki disease in infants: do we need criteria? West J Med 1995;162:322-7.
  3. Anne HR, Stanford TS. Kawasaki syndrome. Pediatr Clin North Am 1999;46:313-29. https://doi.org/10.1016/S0031-3955(05)70120-6
  4. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, American Heart Association. Pediatrics 2004;114:1708- 33. https://doi.org/10.1542/peds.2004-2182
  5. Cowie M, Jourdain P, Maisel A, Dahlstrom U, Follath F, Isnard R, et al. Clinical applications of B-type natriuretic peptide(BNP) testing. Eur Heart J 2003;24:1710-8. https://doi.org/10.1016/S0195-668X(03)00476-7
  6. Saenger AK, Jaffe AS. The use of biomarkers for the evaluation and treatment of patients with acute coronary syndromes. Med Clin North Am 2007;91:657-81. https://doi.org/10.1016/j.mcna.2007.04.001
  7. Cowie M, Mendez G. BNP and congestive heart failure. Prog Cardiovasc Dis 2002;44:293-321. https://doi.org/10.1053/pcad.2002.24599
  8. Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura T, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993;88:82-91. https://doi.org/10.1161/01.CIR.88.1.82
  9. Fried I, Bar-Oz B, Perles Z, Rein AJ, Zonis Z, Nir A. Nterminal Pro-B-type natriuretic peptide levels in acute versus chronic left ventricular dysfunction. J Pediatr 2006;149:28-31. https://doi.org/10.1016/j.jpeds.2006.02.038
  10. Nir A, Lindinger A, Rauh M, Bar-Oz B, Laer S, Schwachtgen L, et al. NT-Pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol 2009;30:3-8. https://doi.org/10.1007/s00246-008-9258-4
  11. Reynolds EW, Ellington JG, Vranicar M, Bada HS. Brain type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatrics 2004;114:1297-304. https://doi.org/10.1542/peds.2004-0525
  12. Ohuchi H, Takasugi H, Ohashi H, Okada Y, Yamada O, Ono Y, et al. Stratification of pediatric heart failure on the basis of neurohormonal and cardiac autonomic nervous activities in patients with congenital heart disease. Circulation 2003; 108:2368–76.
  13. Kawamura T, Wago M, Kawaguchi H, Tahara M, Yuge M. Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease. Pediatr Int 2000;42:241-8. https://doi.org/10.1046/j.1442-200x.2000.01225.x
  14. Lee HJ, Kim HJ, Kim HS, Sohn SJ. NT-pro BNP: A new diagnostic screening tool for Kawasaki disease. Korean J Pediatr 2006;49:539-44. https://doi.org/10.3345/kjp.2006.49.5.539
  15. Dahdah N, Siles A, Fournier A, Cousineau J, Delvin E, Saint- Cyr C, et al. Natriuretic peptide as an adjunctive diagnostic test in the acute phase of Kawasaki disease. Pediatr Cardiol 2009;30:810-7. https://doi.org/10.1007/s00246-009-9441-2
  16. Heo MY, Choi SJ, Kim HS, Sohn SJ. Clinical features of aty　 pical Kawasaki disease. J Korean Pediatr Soc 2002;45:376-82..
  17. Yu YI, Kim DJ, Yum MK, Kim Ns, Lee HB. Clinical study of typical and atypical Kawasaki diseases. J Korean Pediatr Soc 1998;41:237-46.
  18. Kalra PR, Anker SD, Coats AJ. Water and sodium regulation in chronic heart failure : the role of natriuretic peptides and vasopressin. Cardiovasc Res 2001;51:495-509. https://doi.org/10.1016/S0008-6363(01)00297-8
  19. Mukoyama M, Nakao K, Saito Y, Ogawa Y, Hosoda K, Suga S, et al. Increased human brain natriuretic peptide in congestive heart failure. N Engl J Med 1990;323:757-8. https://doi.org/10.1056/NEJM199009133231114
  20. Uusimaa P, Ruskoaho H, Vuolteenaho O, Niemelä M, Lumme J, Ikäheimo M, et al. Plasma vasoactive peptides after acute myocardial infarction in relation to left ventricular dysfunction. Int J Cardiol 1999;69:5–14. https://doi.org/10.1016/S0167-5273(99)00007-8
  21. Masson S, Latini R. Amino-terminal pro-B-type natriuretic peptides and prognosis in chronic heart failure. Am J Cardiol 2008;101:56-60. https://doi.org/10.1016/j.amjcard.2007.11.024
  22. Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, et al. N-terminal pro-B-type natriuretic peptide and longterm mortality in acute coronary syndromes. Circulation 2002; 106:2913-8. https://doi.org/10.1161/01.CIR.0000041661.63285.AE
  23. Bionda C, Bergerot C, Ardail D, Rodriguez-Lafrasse C, Rousson R. Plasma BNP and NT-proBNP assays by automated immunoanalyzers: analytical and clinical study. Ann Clin Lab Sci 2006;36:299–306.
  24. Suda K, Matsumura M, Matsumoto M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int 2003;45:249–54. https://doi.org/10.1046/j.1442-200X.2003.01716.x
  25. Law YM, Ettedgui J, Beerman L, Maisel A, Tofovic S. Comparison of plasma B-type natriuretic peptide levels in single ventricle patients with systemic ventricle heart failure versus isolated cavopulmonary failure. Am J Cardiol 2006;98:520-4. https://doi.org/10.1016/j.amjcard.2006.02.058
  26. Price JF, Thomas AK, Grenier M, Eidem BW, O'Brian Smith E, Denfield SW. et al. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction. Circulation 2006; 114:1063–9. https://doi.org/10.1161/CIRCULATIONAHA.105.608869
  27. Nir A, Lindinger A, Rauh M, Bar-Oz B, Laer S, Schwachtgen L, et al. NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol 2009;30:3-8. https://doi.org/10.1007/s00246-008-9258-4

Cited by

  1. N-terminal Pro-Brain Natriuretic Peptide (NT proBNP) as a Predictive Indicator of Initial Intravenous Immunoglobulin Treatment Failure in Children With Kawasaki Disease: A Retrospective Study vol.34, pp.8, 2010, https://doi.org/10.1007/s00246-013-0724-2
  2. N-terminal pro-brain natriuretic peptide in acute Kawasaki disease correlates with coronary artery involvement vol.25, pp.7, 2010, https://doi.org/10.1017/s1047951114002431
  3. Usefulness of Age-Stratified N-Terminal Prohormone of Brain Natriuretic Peptide for Diagnosing Kawasaki Disease vol.2017, pp.None, 2010, https://doi.org/10.1155/2017/6263121
  4. N-terminal probrain natriuretic peptide as biomarker for diagnosis of Kawasaki disease vol.13, pp.4, 2010, https://doi.org/10.2217/bmm-2018-0324
  5. Serum Ferritin as a Diagnostic Biomarker for Kawasaki Disease vol.41, pp.3, 2010, https://doi.org/10.3343/alm.2021.41.3.318